News Details

On 11 March 2026, the Government of Canada published an Order (SOR/2026-38) in the Canada Gazette, introducing new regulatory amendments to strengthen control over key chemicals used in the illicit production of fentanyl. The Order adds five substances to Schedule VI of the Controlled Drugs and Substances Act (CDSA), thereby establishing long-term controls on their manufacture, import, export, and use. These measures will come into force on 12 April 2026, ensuring continuity after the temporary controls expire.

Five Fentanyl Precursors Brought Under Strict Control

The amendments introduce controls on the following precursor chemicals:

• Phenethyl bromide (CAS 103-63-9)

• Phenethyl chloride (CAS 622-24-2)

• Phenethyl iodide (CAS 17376-04-4)

• Propionic anhydride (CAS 123-62-6)

• Benzyl chloride (CAS 100-44-7)

Phenethyl bromide, phenethyl chloride, phenethyl iodide, and propionic anhydride have been classified as Class A precursors, while benzyl chloride has been designated a Class B precursor. These classifications determine the level of regulatory control, including licensing, registration, and reporting requirements under the Precursor Control Regulations (PCR).

Addressing Public Health and Safety Risks

The regulatory action follows growing concerns regarding the role of precursor chemicals in the illegal synthesis of fentanyl, a highly potent synthetic opioid that has caused significant public health harm in Canada. Health Canada’s scientific assessment confirmed that phenethyl chloride and phenethyl iodide, in addition to already controlled substances, can serve as alternative pathways for illicit fentanyl production. This necessitates their inclusion in the regulatory framework.

There is evidence that phenethyl bromide has been used in clandestine laboratories in Canada, with large quantities being intercepted both domestically and internationally. Meanwhile, propionic anhydride and benzyl chloride have also been linked to illegal drug manufacturing, with seizures reported at the Canadian border and in other jurisdictions.

Transition from Temporary to Permanent Controls

The new measures replace the 2025 Ministerial Order, which temporarily controlled three precursors: phenethyl bromide, propionic anhydride, and benzyl chloride. As these temporary controls are due to expire in 2026, the latest amendments ensure that there will be no regulatory gap, while also expanding the scope to include additional substances that have been identified as emerging risks.

Under the new framework, all regulated activities involving these precursors, such as production, import, export, sale, and possession for commercial purposes, will require appropriate authorization through licences or registrations. This shift from temporary exemptions to established regulatory requirements will strengthen long-term compliance and enforcement.

Supporting Law Enforcement and Border Control Efforts

The amendments form part of Canada’s broader efforts to strengthen border and enforcement measures aimed at disrupting illegal drug supply chains. By formally scheduling these substances, authorities such as the Canada Border Services Agency (CBSA) and law enforcement agencies gain stronger legal tools to intercept shipments and take action against unauthorized activities.

Health Canada has emphasized that these controls will help prevent the diversion of legitimate chemicals into illicit drug production, while maintaining access for legitimate industrial, pharmaceutical, and research purposes under regulated conditions.

Limited Impact on Industry with Strong Public Health Benefits

Regulatory analysis indicates that the amendments will impose minimal administrative and financial burden on stakeholders, including industry and research organizations. While companies will need to comply with licensing, record-keeping, and reporting requirements, the overall cost is expected to remain low.

At the same time, the public health benefits are significant. The measures are intended to reduce the availability of precursor chemicals for illegal fentanyl production, thereby contributing to efforts to reduce overdose deaths, improve community safety, and address organized crime linked to synthetic drugs.

Canada Reinforces Global Leadership on Synthetic Drug Control

Although these substances are not currently controlled under international conventions, Canada’s decision to regulate them reflects a proactive approach to emerging risks in the global drug landscape. The initiative aligns with international efforts to strengthen responses to synthetic drugs and demonstrates Canada’s preventive, science-based approach to chemical regulation.

Overall, the new controls represent a step in limiting access to key fentanyl precursors, thereby reinforcing Canada’s strategy to combat the opioid crisis and protect public health and safety.